DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank

  • Independent data safety monitoring board (DSMB) has recommended a hold on Panbela Therapeutics Inc's (NASDAQ: PBLA) ongoing Phase 1 trial to hold the administration of SBP-101 pending further investigation of visual disturbance adverse events. The company continues to be in communication with the trial investigators.
  • Some patients in the trial had complaints of visual changes, although visual changes were not seen in the SBP-101 monotherapy study.
  • SBP-101 will not be administered to ongoing patients while additional safety information is analyzed. 
  • Patients will continue with the standard drug regimen. All other trial activities continue. Withholding SBP-101 constitutes a "partial clinical hold."
  • SBP-101 is being evaluated when used in combination with gemcitabine and nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDA). The drug candidate received Fast Track and Orphan Drug designation from FDA.
  • Panbela is working to finalize a visual screening program to understand the significance of reported visual changes. 
  • SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition.
  • Price Action: PBLA shares are down 31.7% at $5.60 in the pre-market session on the last check Wednesday.

Posted In: DSMBPancreatic CancerPhase 1 TrialBiotechNewsFDATop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.